ArticleDiscover oncology2026
Development of machine learning and nomogram models to predict lung metastasis and prognosticate survival in breast cancer.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
purposeLung metastasis in breast cancer (BCLM) is a critical determinant of poor prognosis, occurring in approximately 30-50% of advanced cases and associated with significantly reduced median survival. This study aimed to develop machine learning models for predicting BCLM and evaluating prognosis using the SEER database.
methodsData from the SEER database (2018-2021) were analyzed. For the prediction model, 11 independent predictors were identified via univariate and multivariate logistic regression. Machine learning models were developed and evaluated using AUC, accuracy, precision, specificity, recall, F-score. The prognostic model incorporated 12 features through Cox regression, via a nomogram, and validated by C-index, calibration plots, decision curve analysis (DCA), and integrated discrimination improvement (IDI).
resultsAmong 124,505 patients, 168 (0.135%) developed lung metastasis. Multivariate logistic analysis identified HR-/HER2- subtype (OR = 2.701, 95% CI 1.614-4.52) and brain metastasis (OR = 11.088, 95% CI 3.518-34.946) as independent high-risk factors. The LR-based prediction model demonstrated the highest discriminative ability among the evaluated individual models, achieving an AUC of 0.947 (95% CI 0.902-0.977), sensitivity of 0.816, specificity of 0.911, and an F-score of 0.024. Given the extremely low incidence of lung metastasis (0.135%), the low F-score mainly reflected the limited positive predictive value inherent to rare-event prediction scenarios. An online tool ( https://9um39fycfyx4icd6cs8gcw.streamlit.app/ ) was deployed for risk assessment. 12 factors confirmed by multivariate COX regression were incorporated the nomogram. The prognostic model achieved a C-index of 0.79 (se = 0.009), with 1-year and 3-year survival AUCs of 0.86 and 0.62. The 1-year calibration plots showed high consistency between predicted and observed survival (mean absolute error = 0.001; 0.9 quantile error = 0.003). DCA and IDI confirmed improved clinical net benefits compared to traditional TNM models.
conclusionThis study identified key risk factors for BCLM and developed prediction and prognosis models that may assist population-level risk stratification. However, given the rare-event nature of lung metastasis, the prediction model should be interpreted cautiously and is more suitable for risk assessment rather than individual-level screening or diagnostic replacement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.